Sango Kazunori, Takaku Shizuka, Tsukamoto Masami, Niimi Naoko, Yako Hideji
Diabetic Neuropathy Project, Department of Diseases and Infection, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
Front Cell Dev Biol. 2022 Jul 6;10:950623. doi: 10.3389/fcell.2022.950623. eCollection 2022.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were developed as insulinotropic and anti-hyperglycemic agents for the treatment of type 2 diabetes, but their neurotrophic and neuroprotective activities have been receiving increasing attention. Myelin plays a key role in the functional maintenance of the central and peripheral nervous systems, and recent and studies have shed light on the beneficial effects of GLP-1RAs on the formation and protection of myelin. In this article, we describe the potential efficacy of GLP-1RAs for the induction of axonal regeneration and remyelination following nerve lesions and the prevention and alleviation of demyelinating disorders, particularly multiple sclerosis.
胰高血糖素样肽-1受体激动剂（GLP-1RAs）最初是作为促胰岛素分泌和抗高血糖药物开发用于治疗2型糖尿病的，但它们的神经营养和神经保护活性越来越受到关注。髓鞘在中枢和外周神经系统的功能维持中起关键作用，最近的研究揭示了GLP-1RAs对髓鞘形成和保护的有益作用。在本文中，我们描述了GLP-1RAs在神经损伤后诱导轴突再生和髓鞘再生以及预防和减轻脱髓鞘疾病，特别是多发性硬化症方面的潜在疗效。
